FDA approves new type of therapy to treat advanced urothelial cancer - FDA Press Releases

FDA granted accelerated approval to Padcev, a Nectin-4-directed antibody and microtubule inhibitor conjugate, meaning the drug specifically targets cancer cells – in this case, the cell adhesion molecule Nectin-4 which is highly expressed in urothelial cancers

from FDA Press Releases RSS Feed https://ift.tt/2S4qlQ3
via IFTTT